Two new diabetes drugs face tough appraisals from U.S. experts next week, promising a volatile ride for shares in Novo Nordisk, AstraZeneca and Bristol-Myers Squibb.
Investors are nervous about prospects for Novo's Victoza, or liraglutide, and AstraZeneca and Bristol's Onglyza, or saxagliptin, both of which could face safety issues that delay their approval in the key U.S. market.
Worries have been heightened since March 6, when Takeda Pharmaceutical said the U.S. Food and Drug Administration (FDA) needed more data to review its new diabetes drug alogliptin, sending the Japanese group's stock tumbling.
More
No comments:
Post a Comment